Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
6.88 USD | +2.69% | -2.96% | -16.61% |
04-01 | Titan Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
01-26 | Titan Pharmaceuticals Regains Compliance With Nasdaq Listing Rule | MT |
Business Summary
Number of employees: 4
Sales per Business
USD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
Pharmaceutical Products
100.0
%
| 1 | 100.0 % | 0 | 100.0 % | -66.97% |
Sales per region
USD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
United States
100.0
%
| 1 | 100.0 % | 0 | 100.0 % | -66.97% |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
Avraham Ben-Tzvi
BRD | Director/Board Member | 53 | 22-08-14 |
Gim Shen Seow
CEO | Chief Executive Officer | 42 | 23-10-11 |
Brynner Chiam
BRD | Director/Board Member | - | 23-10-11 |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 1 | 914,234 | 498,544 ( 54.53 %) | 0 | 54.53 % |
Stock B | 0 | 950,000 | 0 | 0 |
Company contact information
Titan Pharmaceuticals, Inc.
400 Oyster Point Boulevard Suite 505
94080-1958, South San Francisco
+650 244 4990
http://www.titanpharm.comSector
1st Jan change | Capi. | |
---|---|---|
-16.61% | 6.29M | |
+26.08% | 662B | |
+21.85% | 546B | |
-4.77% | 359B | |
+16.97% | 323B | |
+5.69% | 290B | |
+13.68% | 234B | |
+3.65% | 198B | |
-11.12% | 194B | |
+8.08% | 167B |
- Stock Market
- Equities
- TTNP Stock
- Company Titan Pharmaceuticals, Inc.